drugset
Drugs / Naltrexone
last change 3 days ago re-read 2 minutes ago

Naltrexone

also known as Vivitrol · XR-NTX · Revia · NTX · NALTREXONE HYDROCHLORIDE · LDN · Extended release naltrexone · naltrexone HCl · +20 more

Small molecule targets TLR4 via inhibition

Developed for
alcohol dependence · opiate dependence · obesity disorder · alcohol-related disorders · substance-related disorder · major depressive disorder · binge eating disorder · cocaine dependence
+88 more · nicotine dependence · alcohol abuse · heroin dependence · methamphetamine dependence · bipolar disorder · COVID-19 · depressive disorder · migraine disorder · schizophrenia · attention deficit-hyperactivity disorder · chronic pain syndrome · fibromyalgia · pathological gambling · schizoaffective disorder · substance abuse · cannabis dependence · eating disorder · osteoarthritis · stereotypic movement disorder · anorexia nervosa · atopic eczema · breast cancer · bulimia nervosa · Crohn disease · melanoma · myalgic encephalomeyelitis/chronic fatigue syndrome · obsessive-compulsive disorder · opioid abuse · psoriatic arthritis · type 2 diabetes mellitus · alcohol-induced disorders · alcoholic liver disease · amphetamine abuse · borderline personality disorder · brain injury · Charcot-Marie-Tooth disease · Charcot-Marie-Tooth disease type 1A · cirrhosis of liver · cocaine abuse · complex regional pain syndrome · complex regional pain syndrome type 1 · complex regional pain syndrome type 2 · corneal ulcer · dermatitis · diabetic polyneuropathy · drug dependence · dry eye syndrome · endometriosis · frontal fibrosing alopecia · headache disorder · hypoglycemia · impulse control disorder · interstitial cystitis · kidney cancer · lichen planopilaris · long COVID-19 · malignant glioma · metastatic prostate carcinoma · morbid obesity · multiple sclerosis · neurological pain disorder · neuropathy, painful · persian gulf syndrome · pervasive developmental disorder · post-traumatic stress disorder · post-viral disorder · prostate cancer · psoriasis · radiculopathy · schizophreniform disorder · spinal cord injury · tuberculosis · type 1 diabetes mellitus · ulcerative colitis · vulvodynia · alcohol-induced mental disorder · dissociative disorder · eosinophilic granulomatosis with polyangiitis · fibrotic liver disease · kleptomania · metabolic dysfunction-associated steatotic liver disease · microscopic polyangiitis · polyarteritis nodosa · psychiatric disorder · pyromania · sexual disorder · Takayasu arteritis · trichotillomania
Investigated by
National Institute on Drug Abuse (NIDA) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · Yale University · Alkermes, Inc. · New York State Psychiatric Institute · Orexigen Therapeutics, Inc
+231 more · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · University of Pennsylvania · Pfizer · Allodynic Therapeutics, Inc · Stanford University · University of California, Los Angeles · Columbia University · Medical University of South Carolina · University of Minnesota · AgelessRx · Bausch Health Americas, Inc. · Brown University · Johns Hopkins University · NYU Langone Health · Shenzhen Sciencare Medical Industries Co., Ltd. · The Emmes Company, LLC · The University of Texas Health Science Center, Houston · University of California, San Francisco · University of Oslo · Alza Corporation · Brigham and Women's Hospital · Centre for Addiction and Mental Health · Friends Research Institute, Inc. · Go Medical Industries Pty Ltd · Massachusetts General Hospital · National Institute of Mental Health (NIMH) · Research Foundation for Mental Hygiene, Inc. · State University of New York - Upstate Medical University · UConn Health · US Department of Veterans Affairs · University of Alabama at Birmingham · University of Texas Southwestern Medical Center · VA Office of Research and Development · Akyso Therapeutics, LLC · Bankole Johnson · Boston Medical Center · Cephalon · Children's Mercy Hospital Kansas City · Clinilabs, Inc. · Elite Laboratories, Inc · Haukeland University Hospital · Indiana University · Institute of Liver and Biliary Sciences, India · Marta Peciña, MD PhD · Mclean Hospital · Milton S. Hershey Medical Center · National Health and Medical Research Council, Australia · National Institutes of Health (NIH) · Oregon Health and Science University · Oslo University Hospital · Seoul National University Hospital · St. Joseph's Healthcare Hamilton · The Hospital of Vestfold · The Research Council of Norway · United States Department of Defense · University of Chicago · University of Colorado, Denver · University of Kansas Medical Center · University of North Carolina, Chapel Hill · University of Sydney · VA Boston Healthcare System · VA Connecticut Healthcare System · Academic Medical Center - University of Amsterdam · Albert Einstein Healthcare Network · Alberta Health services · Aliri Bioanalysis · American Diabetes Association · American Fibromyalgia Syndrome Association · American Psychological Foundation · American Society for Metabolic and Bariatric Surgery · Annette C. Toledano MD · Ardena · Asan Medical Center · Avekshan LLC · all 237 on the full record

Regulatory milestones approvals, filings & regulatory actions · 4 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) Mysimba — 2015-03-26 europa.eu ↗
Label expansion US (FDA) VIVITROL — 2010-10-12 fda.gov ↗
Label expansion US (FDA) REVIA — 1994-12-30 fda.gov ↗
Approved US (FDA) REVIA — 1984-11-20 fda.gov ↗

Trials 315 · started per year

today
US approved 1984
EU approved 2015
1
2
2
4
3
2
7
2
8
13
3
13
15
16
14
9
4
11
14
15
10
11
18
16
11
6
8
26
11
10
11
7
11
198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 09 trials
Phase 0 NCT04553263 Jun 2023 → Jan 2025 attention deficit-hyperactivity disorder, cognitive disorder, substance abuse University of California, Los Angeles Withdrawn No outcome recorded
Phase 0 NCT05509257 Sep 2022 → Sep 2026 expected anorexia nervosa, binge eating disorder, bulimia nervosa Children's Mercy Hospital Kansas City Recruiting No outcome recorded
Phase 0 NCT05007561 Nov 2021 → Apr 2027 expected — San Diego State University Recruiting No outcome recorded
Phase 0 NCT04977674 Sep 2021 → Feb 2023 major depressive disorder King's College London Completed No outcome recorded
Phase 0 NCT04935931 Jul 2021 → Jun 2022 binge eating disorder Children's Mercy Hospital Kansas City Completed No outcome recorded
Phase 0 NCT04562779 Jan 2021 → Jan 2022 alcohol dependence Denver Health and Hospital Authority Completed No outcome recorded
Phase 0 NCT03447743 Sep 2019 → Mar 2022 opiate dependence Michele Staton Completed No outcome recorded
Phase 0 NCT03766893 Sep → Dec 2018 opiate dependence Lifespan Completed No outcome recorded
Phase 0 NCT00667771 Apr 2008 → Dec 2010 alcohol dependence National Institute on Alcohol Abuse and Alcoholism (NIAAA) Completed No outcome recorded
Phase 138 trials
Phase 1 NCT07224087 Sep 2026 → Dec 2027 expected obesity disorder Medical University of South Carolina Not yet recruiting No outcome recorded
Phase 1 NCT07064564 Apr 2026 → Jun 2027 expected opiate dependence Akyso Therapeutics, LLC Not yet recruiting No outcome recorded
Phase 1 NCT06374290 Jul → Dec 2024 — The University of Texas Health Science Center, Houston Terminated No outcome recorded
Phase 1 NCT06216132 Jun 2024 → Apr 2025 substance-related disorder Akyso Therapeutics, LLC Completed No outcome recorded
Phase 1 NCT05968690 Sep 2023 → Sep 2026 expected melanoma Sarah Weiss Recruiting No outcome recorded
Phase 1 NCT05919017 Jun → Dec 2023 — Shenzhen Sciencare Medical Industries Co., Ltd. Unknown No outcome recorded
Phase 1 NCT04828694 Jun 2022 → Feb 2023 opiate dependence BioCorRx Inc Completed No outcome recorded
Phase 1 NCT05304364 Mar → Oct 2022 substance-related disorder Delpor, Inc. Completed No outcome recorded
Phase 1 NCT04708327 Dec 2021 → Jun 2022 COVID-19 Cytocom, Inc. Unknown No outcome recorded
Phase 1 NCT04958876 Oct → Dec 2021 — Scilex Pharmaceuticals, Inc. Completed No outcome recorded
Phase 1/215 trials
Phase 1/2 NCT07398404 Sep 2026 → Dec 2030 expected obesity disorder Medical University of South Carolina Not yet recruiting No outcome recorded
Phase 1/2 NCT04854551 May 2021 → Apr 2022 alcohol-related disorders University of Colorado, Denver Completed No outcome recorded
Phase 1/2 NCT03447782 Jul 2018 → Nov 2020 headache disorder Boston Children's Hospital Completed No outcome recorded
Phase 1/2 NCT03278886 Jul → Dec 2018 HIV infectious disease, alcohol-related disorders Boston Medical Center Completed No outcome recorded
Phase 1/2 NCT02885311 Jan 2017 → Oct 2018 alcohol abuse, alcohol dependence Northwell Health Completed No outcome recorded
Phase 1/2 NCT02696512 Mar 2016 → Mar 2017 brain injury International Brain Research Foundation Unknown No outcome recorded
Phase 1/2 NCT02461927 Jan 2015 → Oct 2023 alcohol dependence, major depressive disorder VA Office of Research and Development Completed No outcome recorded
Phase 1/2 NCT02088177 Oct 2014 → Mar 2016 cannabis dependence New York State Psychiatric Institute Completed No outcome recorded
Phase 1/2 NCT01982643 Nov 2013 → Feb 2015 methamphetamine dependence Walter Ling Completed No outcome recorded
Phase 1/2 NCT01895036 Feb 2011 → Sep 2013 opiate dependence New York State Psychiatric Institute Completed No outcome recorded
Phase 294 trials
Phase 2 NCT07285473 Sep 2026 → Apr 2028 expected myalgic encephalomeyelitis/chronic fatigue syndrome University of Alabama at Birmingham Not yet recruiting No outcome recorded
Phase 2 NCT07249554 Sep 2026 → Jul 2028 expected alcohol-related disorders Johns Hopkins University Not yet recruiting No outcome recorded
Phase 2 NCT05382091 Jul 2026 → Jul 2028 expected opiate dependence Go Medical Industries Pty Ltd Not yet recruiting No outcome recorded
Phase 2 NCT07224009 Jul 2026 → Jan 2028 expected metastatic prostate carcinoma University of Arkansas Not yet recruiting No outcome recorded
Phase 2 NCT06622239 Jun 2026 → Feb 2027 expected — Seoul National University Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07132177 Nov 2025 → Apr 2026 alcohol abuse Brigham and Women's Hospital Completed No outcome recorded
Phase 2 NCT06723561 Feb 2025 → Jun 2026 overdue neurological pain disorder, spinal cord injury Medical College of Wisconsin Active not recruiting No outcome recorded
Phase 2 NCT05685225 Jan → Dec 2025 migraine disorder Allodynic Therapeutics, Inc Withdrawn No outcome recorded
Phase 2 NCT05940324 Feb 2024 → Nov 2028 expected obsessive-compulsive disorder Stanford University Recruiting No outcome recorded
Phase 2 NCT05430152 Jan 2024 → Feb 2026 post-viral disorder Luis Nacul Completed No outcome recorded
Phase 2/316 trials
Phase 2/3 NCT06633900 Apr 2025 → Apr 2027 expected — University of California, San Francisco Recruiting No outcome recorded
Phase 2/3 NCT07092618 Dec 2024 → Aug 2025 overdue — AgelessRx Recruiting No outcome recorded
Phase 2/3 NCT05073679 Apr 2022 → May 2024 anorexia nervosa, bulimia nervosa, impulse control disorder Rosemary Claire Roden Terminated No outcome recorded
Phase 2/3 NCT04605081 Jan 2022 → May 2027 expected eating disorder, obesity disorder Yale University Active not recruiting No outcome recorded
Phase 2/3 NCT04662801 Aug 2021 → Sep 2022 obesity disorder Yale University Completed No outcome recorded
Phase 2/3 NCT04599478 Jun 2021 → Dec 2025 overdue eating disorder, obesity disorder Yale University Active not recruiting No outcome recorded
Phase 2/3 NCT03946111 Aug 2019 → Dec 2024 binge eating disorder, obesity disorder Yale University Completed No outcome recorded
Phase 2/3 NCT03539900 Apr 2018 → Apr 2022 binge eating disorder Yale University Completed No outcome recorded
Phase 2/3 NCT03047005 Aug 2017 → Dec 2021 binge eating disorder, obesity disorder Yale University Completed No outcome recorded
Phase 2/3 NCT03185143 Jun 2017 → May 2018 migraine disorder Allodynic Therapeutics, Inc Completed No outcome recorded
Phase 345 trials
Phase 3 NCT07433413 Mar 2026 → Apr 2027 expected alcohol-related disorders Shenzhen Sciencare Medical Industries Co., Ltd. Not yet recruiting No outcome recorded
Phase 3 NCT07475546 Jul 2025 → Apr 2026 overdue — AgelessRx Active not recruiting No outcome recorded
Phase 3 NCT05827159 Aug 2024 → Dec 2027 expected alcohol-related disorders Yale University Recruiting No outcome recorded
Phase 3 NCT06233799 Jul 2024 → Oct 2026 expected amphetamine abuse, methamphetamine dependence National Institute on Drug Abuse (NIDA) Active not recruiting No outcome recorded
Phase 3 NCT05157698 Jan 2022 → Jan 2027 expected obesity disorder Yale University Active not recruiting No outcome recorded
Phase 3 NCT05092841 Sep 2021 → Mar 2024 Charcot-Marie-Tooth disease type 1A Tasly GeneNet Pharmaceuticals Co., Ltd Completed No outcome recorded
Phase 3 NCT04762758 Mar 2021 → Apr 2024 Charcot-Marie-Tooth disease Pharnext S.C.A. Unknown No outcome recorded
Phase 3 NCT03970330 Jan 2020 → Jun 2021 endometriosis Milton S. Hershey Medical Center Terminated No outcome recorded
Phase 3 NCT03232346 Aug 2017 → Jun 2021 opiate dependence New York State Psychiatric Institute Completed No outcome recorded
Phase 3 NCT03479086 Jun 2017 → Nov 2020 alcohol dependence South West Sydney Local Health District Unknown No outcome recorded
Phase 471 trials
Phase 4 NCT07213466 Jan 2026 → Feb 2028 expected bipolar I disorder, bipolar II disorder, obesity disorder, schizoaffective disorder Mayo Clinic Recruiting No outcome recorded
Phase 4 NCT06620562 Jun 2025 → Jun 2028 expected morbid obesity Laval University Recruiting No outcome recorded
Phase 4 NCT06854614 Mar 2025 → Apr 2027 expected obesity disorder The Cleveland Clinic Active not recruiting No outcome recorded
Phase 4 NCT06605703 Sep 2024 → Feb 2026 obesity disorder WW International Inc Completed No outcome recorded
Phase 4 NCT06809166 Jul 2024 → Jan 2026 overdue obesity disorder The Royal's Institute of Mental Health Research Recruiting No outcome recorded
Phase 4 NCT06426303 May 2024 → Dec 2028 expected alcohol-related disorders Oregon Health and Science University Recruiting No outcome recorded
Phase 4 NCT06306157 Jan 2024 → Aug 2026 overdue complex regional pain syndrome type 1, complex regional pain syndrome type 2 Hospital for Special Surgery, New York Enrolling by invitation No outcome recorded
Phase 4 NCT05919797 Jun 2023 → Jun 2027 expected obesity disorder Columbia University Recruiting No outcome recorded
Phase 4 NCT05537935 Apr 2023 → Jun 2027 expected HIV infectious disease, neuropathy, painful Emory University Recruiting No outcome recorded
Phase 4 NCT04739995 Jun 2022 → Oct 2024 — Fundació Sant Joan de Déu Unknown No outcome recorded
Phase not applicable27 trials
— NCT07641283 Jun 2026 → Dec 2027 expected stereotypic movement disorder Seoul National University Hospital Not yet recruiting No outcome recorded
— NCT06175507 Dec 2023 → Mar 2025 alcoholic liver disease Institute of Liver and Biliary Sciences, India Unknown No outcome recorded
— NCT05053503 May 2022 → Apr 2025 opiate dependence, substance withdrawal syndrome Spark Biomedical, Inc. Completed No outcome recorded
— NCT05924893 Jan 2021 → Jun 2022 corneal ulcer Minia University Completed No outcome recorded
— NCT04391764 Dec 2020 → Oct 2022 cirrhosis of liver Institute of Liver and Biliary Sciences, India Completed No outcome recorded
— NCT03581630 Jul 2017 → Jul 2018 breast cancer, obesity disorder Gangnam Severance Hospital Completed No outcome recorded
— NCT02818036 Aug 2016 → Jun 2018 — Tristen Inagaki Completed No outcome recorded
— NCT02965768 Jan 2016 → Aug 2022 myalgic encephalomeyelitis/chronic fatigue syndrome University of Alabama at Birmingham Withdrawn No outcome recorded
— NCT02502162 Jun 2015 → Jul 2027 expected complex regional pain syndrome Stanford University Recruiting No outcome recorded
— NCT02317744 Dec 2014 → Sep 2016 binge eating disorder Yale University Completed No outcome recorded
Also used as a comparator or background therapy in 114 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT04166071 Comparator Dec 2021 → Sep 2026 expected — University of California, Los Angeles Enrolling by invitation No outcome recorded
Phase 0 NCT01175512 Comparator Jul 2010 → Dec 2011 opiate dependence University of California, San Francisco Completed No outcome recorded
Phase 118 trials
Phase 1 NCT07269873 Comparator Mar → Dec 2026 expected — BioCorRx Pharmaceuticals Inc Recruiting No outcome recorded
Phase 1 NCT05620940 Comparator Sep 2024 → Dec 2025 overdue alcohol dependence, multiple sclerosis, opiate dependence Inventage Lab., Inc. Recruiting No outcome recorded
Phase 1 NCT05002946 Comparator Jan → Apr 2022 — Scilex Pharmaceuticals, Inc. Completed No outcome recorded
Phase 1 NCT05090280 Background Dec 2021 → Apr 2023 — Ensysce Biosciences Completed No outcome recorded
Phase 1 NCT05043766 Background Sep 2021 → Mar 2022 — Ensysce Biosciences Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT07221565 Background Oct 2025 → Oct 2034 expected autoinflammatory syndrome, immune dysregulation, autoimmunity, and autoinflammation, multiple sclerosis, rheumatoid arthritis +1 Truway Health, Inc. Enrolling by invitation No outcome recorded
Phase 1/2 NCT01246401 Comparator Mar 2011 → Mar 2016 AIDS, opiate dependence Yale University Completed No outcome recorded
Phase 231 trials
Phase 2 NCT06845124 Background Jul 2025 → Apr 2028 expected alcohol dependence Central Institute of Mental Health, Mannheim Recruiting No outcome recorded
Phase 2 NCT06366724 Comparator Sep 2024 → Sep 2026 expected long COVID-19, myalgic encephalomeyelitis/chronic fatigue syndrome Brigham and Women's Hospital Recruiting No outcome recorded
Phase 2 NCT04454411 Comparator Aug 2022 → Aug 2024 opiate dependence University of Pennsylvania Terminated No outcome recorded
Phase 2 NCT04738773 Comparator Jun 2021 → Jul 2022 pathological gambling University of Sao Paulo Unknown No outcome recorded
Phase 2 NCT04052139 Comparator Jan → Nov 2021 HIV infectious disease, alcohol-related disorders, chronic pain syndrome Boston Medical Center Completed No outcome recorded
Phase 2/316 trials
Phase 2/3 NCT05093296 Background Dec 2021 → Jul 2023 alcohol dependence Central Institute of Mental Health, Mannheim Completed No outcome recorded
Phase 2/3 NCT04345718 Comparator Aug 2021 → Aug 2025 opiate dependence Gavin Bart Completed No outcome recorded
Phase 2/3 NCT04408313 Comparator Oct 2020 → May 2026 overdue opiate dependence Friends Research Institute, Inc. Active not recruiting No outcome recorded
Phase 2/3 NCT04139213 Background Jul 2019 → Sep 2022 opiate dependence Lifespan Unknown No outcome recorded
Phase 2/3 NCT04502251 Comparator Aug 2018 → Aug 2019 fibromyalgia Centro Universitario La Salle Completed No outcome recorded
Phase 315 trials
Phase 3 NCT05458609 Comparator Feb 2023 → Jan 2024 alcohol-related disorders Baylor College of Medicine Completed No outcome recorded
Phase 3 NCT02652585 Comparator Feb 2016 → Aug 2017 alcohol dependence Technical University Dresden Completed No outcome recorded
Phase 3 NCT02579759 Comparator Dec 2015 → Mar 2018 Charcot-Marie-Tooth disease type 1A Pharnext S.C.A. Completed No outcome recorded
Phase 3 NCT02537574 Comparator Aug 2015 → Oct 2016 substance-related disorder Alkermes, Inc. Completed No outcome recorded
Phase 3 NCT01625091 Comparator Dec 2012 → Jul 2016 HIV infectious disease University of Florida Completed No outcome recorded
Phase 424 trials
Phase 4 NCT06845345 Comparator Apr 2025 → Jul 2027 expected fibrotic liver disease, hyperlipidemia, hypertensive disorder, metabolic dysfunction-associated steatotic liver disease +2 Carmen Dietvorst Enrolling by invitation No outcome recorded
Phase 4 NCT06098079 Comparator Jan 2024 → Jan 2029 expected obesity disorder Currax Pharmaceuticals Active not recruiting No outcome recorded
Phase 4 NCT06140420 Comparator Aug 2023 → Feb 2025 — Texas Tech University Terminated No outcome recorded
Phase 4 NCT04902625 Comparator Mar 2023 → Mar 2025 morbid obesity Zuyderland Medical Center Unknown No outcome recorded
Phase 4 NCT05028062 Comparator Mar 2022 → Jul 2027 expected alcohol dependence University of Pennsylvania Recruiting No outcome recorded
Phase not applicable6 trials
— NCT02194764 Background Jun → Jul 2014 — Xhale Assurance Completed No outcome recorded
— NCT02138396 Background Jan 2014 — INSYS Therapeutics Inc Completed No outcome recorded
— NCT01327326 Comparator Dec 2011 → Jul 2012 temporomandibular joint disorder University of Florida Withdrawn No outcome recorded
— NCT01220414 Comparator Sep 2010 → Jan 2013 — University of Wisconsin, Madison Completed No outcome recorded
— NCT01077310 Comparator Aug 2010 → Aug 2015 AIDS, alcohol abuse, alcohol dependence Yale University Completed No outcome recorded

Press releases naming this drug 5 releases

DateIssuerRelease
2016-08-19 Pfizer FDA Approves TROXYCA® ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain pfizer.com ↗
2016-06-08 Pfizer Pfizer Announces FDA Advisory Committees’ Recommend ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules for Approval pfizer.com ↗
2015-02-13 Pfizer Pfizer Announces FDA Acceptance for Review of a New Drug Application for ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) pfizer.com ↗
2014-10-21 Takeda Takeda and Orexigen Announce Availability of CONTRAVE ® (naltrexone HCl and bupropion HCl) Extended-Release Tablets for Chronic Weight Management in Obese Adults takeda.com ↗
2014-09-11 Takeda Takeda and Orexigen Announce FDA Approval of Contrave ® (naltrexone HCI and bupropion HCI) Extended-release Tablets for Chronic Weight Management takeda.com ↗

Evidence & citations 33 cited values

Every value below carries the sentence it was read from. 462 sources stand behind the page.

FieldValueCited text
Known as naltrexone “Naltrexone, an orally semisynthetic opiate antagonist, is FDA-approved for the treatment of heroin/alcohol addiction, and low-dose naltrexone (LDN) has been observed to improve...” PMID 35001215 ↗ Jan 2022
413

“Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12,...” NCT02696512 ↗

“Combination of (RS)-baclofen, naltrexone hydrochloride and D-sorbitol, termed PXT3003, improved myelination in the Pmp22 transgenic co-culture cellular model, and moderately...” PMID 25491744 ↗ Dec 2014

“Participants categorized as not experiencing early weight loss at the end of the first month of treatment will continue BWL plus a weight loss medication (Naltrexone Bupropion)...” NCT04662801 ↗

“A PHASE 1, OPEN-LABEL, EXPLORATORY, FIXED-SEQUENCE, PHARMACOKINETIC SINGLE ASCENDING DOSE STUDY OF IVL3004 VERSUS VIVITROL® (NALTREXONE) LONG-ACTING INJECTABLE (LAI) AND...” NCT05620940 ↗

“An Open-Label Study Assessing the Safety and Efficacy of Naltrexone Sustained Release (SR) in Combination With Bupropion Sustained Release (SR) in Overweight and Obese,...” NCT00563563 ↗

“The purpose of this study is to determine if the opioid agonist effects of doses of 4/1 mg, 8/2 mg, and 16/4 mg of buprenorphine/naloxone can be completely blocked by 50 mg of...” NCT00733720 ↗

“ALO-02 capsules, intended to deter abuse, contain pellets of extended-release oxycodone hydrochloride (HCl), an opioid agonist, surrounding sequestered naltrexone HCl, an...” PMID 25724154 ↗ Apr 2015

“CONTRAVE® will be titrated up to a therapeutic dose (Naltrexone 32mg/Bupropion 360mg) over a 4-week period as per clinical guidelines, and what is typical in the LEAF clinic.” NCT06809166 ↗

“Injectable naltrexone will be used, at a dose of 4cc (380mg of naltrexone), administered by intramuscular injection to the buttocks (alternating sides monthly).” NCT04408313 ↗

“Naltrexone 50 mg will be taken orally every 12 hours, from the evening of Day 00 (13 hours prior to IMP application), until the evening of the patch removal.” NCT03975010 ↗

“It also evaluated the adjunctive efficacy of the Food and Drug Administration (FDA)-approved alcoholism pharmacotherapy, naltrexone, relative to placebo.” PMID 22089316 ↗ Nov 2011

“The injection is a liquid medication in the amount of 380 mg naltrexone in 4 cc volume (about 1 teaspoon) and will last in your body for about 30 days.” NCT04219540 ↗

“Community standard medication for opioid use disorder (e.g., methadone, sublingual buprenorphine, naltrexone) initiated prior to hospital discharge.” NCT04345718 ↗

“Intervention Subjects were randomized 1:1:1 to receive naltrexone, acamprosate or disulfiram, 50 mg, 1998 mg or 200 mg correspondingly per day.” NCT00435435 ↗

“Naltrexone/bupropion combination (on-going blinded pharmacotherapy from acute treatment consisting of either naltrexone/bupropion or placebo)” NCT03063606 ↗

“BICX104 is an eroding implantable pellet that contains 1 g naltrexone and 11 mg magnesium stearate that will be inserted subcutaneously.” NCT04828694 ↗

“Participants will take Mysimba twice daily at a total dose of 32 mg/360 mg naltrexone/bupropion per day for a duration of six months.” NCT06845345 ↗

“Vivitrol®, an extended release formulation of naltrexone, was recently approved by the FDA for the treatment of opioid dependence” NCT01556425 ↗

“Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally.” NCT04589130 ↗

“Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally.” NCT04587843 ↗

“Efficacy and Safety of VIVITROL® (Naltrexone for Extended-release Injectable Suspension) in Adults With Opioid Dependence” NCT00678418 ↗

“One medication that could address this treatment gap is extended-release naltrexone (XR-NTX; marketed as Vivitrol®).” NCT01932801 ↗

“Participants were randomized to receive placebo (n=4454) or naltrexone, 32 mg/d, and bupropion, 360 mg/d (n=4456).” PMID 26954408 ↗ Mar 2016

“Thirteen months of naltrexone treatment for opioid use disorder (injection at baseline, followed by 4 implants).” NCT03290391 ↗

“increase adherence to extended-release naltrexone (XR-NTX) during the transition from jail to the community” NCT03447743 ↗

“Long-acting, injectable form of naltrexone (Vivitrol) will be administered once per month” NCT00476242 ↗

“ALO-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride Extended-release Capsules)” NCT01746901 ↗

“with Vivitrol (naltrexone) 380mg intramuscular injection (IM) (given every 4 weeks)” NCT03852628 ↗

“Naltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)” NCT01764386 ↗

“(RS)-baclofen, naltrexone hydrochloride and D-sorbitol oral fixed dose combination” NCT05092841 ↗

“Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues” PMID 23571420 ↗ Apr 2013

“low-dose oral naltrexone (NTX), combined with a brief buprenorphine (BUP) taper” PMID 29674251 ↗ Apr 2018

“VIVITROL (naltrexone for extended-release injectable suspension)” NCT01100853 ↗

“extended-release naltrexone (XR-NTX, Vivitrol®; Alkermes Inc.)” PMID 27282118 ↗ Jun 2016

“naltrexone (NTX) blocks the rewarding effects of MPH in mice.” NCT03769064 ↗

“Naltrexone 50mg orally once daily will give for 12 weeks” NCT06175507 ↗

“naltrexone hydrochloride capsules 4.5 mg each” NCT04708327 ↗

“naltrexone 25 mg oral capsule once per day” NCT00502216 ↗

“4 days of ascending oral naltrexone doses” NCT01377610 ↗

“Naltrexone HCL, 4.5 mg, Once a day.” NCT02502162 ↗

“Naltrexone 50mg memantine 20mg” NCT01519063 ↗

“Prescription for naltrexone” NCT01032135 ↗

NCT01053078 ↗

NCT04502251 ↗

NCT00467558 ↗

NCT00223275 ↗

NCT03386448 ↗

NCT00467454 ↗

NCT00419731 ↗

NCT02978417 ↗

NCT01638377 ↗

NCT04276259 ↗

NCT05509257 ↗

NCT00444418 ↗

NCT02088177 ↗

NCT07224009 ↗

NCT01717963 ↗

NCT00714584 ↗

NCT05430152 ↗

NCT01133301 ↗

NCT01449565 ↗

NCT05685225 ↗

NCT02750748 ↗

NCT04365985 ↗

NCT07224087 ↗

NCT02593474 ↗

NCT02616315 ↗

NCT00656630 ↗

NCT00156923 ↗

NCT00719095 ↗

NCT00218426 ↗

NCT01690546 ↗

NCT06374290 ↗

NCT03447782 ↗

NCT00156936 ↗

NCT00053677 ↗

NCT04325802 ↗

NCT00743145 ↗

NCT00004554 ↗

NCT01179191 ↗

NCT05458609 ↗

NCT01428583 ↗

NCT04115020 ↗

NCT03078075 ↗

NCT05087771 ↗

NCT00938886 ↗

NCT02736474 ↗

NCT07014644 ↗

NCT01893827 ↗

NCT01557257 ↗

NCT01227044 ↗

NCT05043766 ↗

NCT04480554 ↗

NCT00793780 ↗

NCT01560013 ↗

NCT03482479 ↗

NCT00398957 ↗

NCT00105482 ↗

NCT00403117 ↗

NCT03201393 ↗

NCT00976066 ↗

NCT05537935 ↗

NCT00204243 ↗

NCT05827159 ↗

NCT01380093 ↗

NCT01810185 ↗

NCT00834080 ↗

NCT04562779 ↗

NCT01296646 ↗

NCT01650350 ↗

NCT00238914 ↗

NCT03766893 ↗

NCT01402492 ↗

NCT00318162 ↗

NCT00145847 ↗

NCT01115894 ↗

NCT04154033 ↗

NCT00218569 ↗

NCT03660475 ↗

NCT00984360 ↗

NCT01825447 ↗

NCT00218660 ↗

NCT00398008 ↗

NCT03879460 ↗

NCT04716881 ↗

NCT00015080 ↗

NCT00379197 ↗

NCT04599478 ↗

NCT03194555 ↗

NCT02543944 ↗

NCT01389167 ↗

NCT00135759 ↗

NCT04052139 ↗

NCT04756128 ↗

NCT00756990 ↗

NCT00115037 ↗

NCT05002946 ↗

NCT02391571 ↗

NCT02735603 ↗

NCT02806440 ↗

NCT07221565 ↗

NCT01866098 ↗

NCT00167232 ↗

NCT07333638 ↗

NCT05382091 ↗

NCT00461890 ↗

NCT02032433 ↗

NCT01882361 ↗

NCT01780233 ↗

NCT01155869 ↗

NCT02698215 ↗

NCT02446002 ↗

NCT00364871 ↗

NCT02696434 ↗

NCT01211769 ↗

NCT01218997 ↗

NCT05940324 ↗

NCT03581630 ↗

NCT02194764 ↗

NCT05093296 ↗

NCT04678895 ↗

NCT04270877 ↗

NCT04817410 ↗

NCT02445339 ↗

NCT05919017 ↗

NCT00711477 ↗

NCT04604678 ↗

NCT00383045 ↗

NCT04757506 ↗

NCT04604704 ↗

NCT05968690 ↗

NCT01673594 ↗

NCT03658330 ↗

NCT02842073 ↗

NCT04605081 ↗

NCT02745912 ↗

NCT01180647 ↗

NCT01220414 ↗

NCT00734461 ↗

NCT02965768 ↗

NCT04958876 ↗

NCT01015066 ↗

NCT04854551 ↗

NCT06233799 ↗

NCT00182572 ↗

NCT07213466 ↗

NCT05053503 ↗

NCT03045341 ↗

NCT05919797 ↗

NCT00663117 ↗

NCT05262270 ↗

NCT00317031 ↗

NCT00018213 ↗

NCT04977674 ↗

NCT07285473 ↗

NCT04738773 ↗

NCT01528007 ↗

NCT00777062 ↗

NCT03851731 ↗

NCT07132177 ↗

NCT02557984 ↗

NCT07475546 ↗

NCT00027079 ↗

NCT04322526 ↗

NCT00366626 ↗

NCT01101815 ↗

NCT03113409 ↗

NCT03132571 ↗

NCT00855972 ↗

NCT00065936 ↗

NCT00124839 ↗

NCT03479086 ↗

NCT03047005 ↗

NCT00567034 ↗

NCT01471145 ↗

NCT00000195 ↗

NCT00831272 ↗

NCT00000196 ↗

NCT05073679 ↗

NCT06622239 ↗

NCT04575194 ↗

NCT06306157 ↗

NCT01874951 ↗

NCT04391764 ↗

NCT01174914 ↗

NCT00129246 ↗

NCT00271024 ↗

NCT01359930 ↗

NCT01057862 ↗

NCT00817089 ↗

NCT07249554 ↗

NCT01175512 ↗

NCT00000307 ↗

NCT06854614 ↗

NCT00399295 ↗

NCT00567255 ↗

NCT00614328 ↗

NCT03854942 ↗

NCT00650182 ↗

NCT01625611 ↗

NCT03946111 ↗

NCT00675961 ↗

NCT01342549 ↗

NCT07064564 ↗

NCT04762758 ↗

NCT02324725 ↗

NCT06426303 ↗

NCT02617628 ↗

NCT01245647 ↗

NCT01052831 ↗

NCT00920829 ↗

NCT00775229 ↗

NCT06723561 ↗

NCT00018824 ↗

NCT02537197 ↗

NCT01415895 ↗

NCT02165930 ↗

NCT04649892 ↗

NCT00326807 ↗

NCT00183196 ↗

NCT00142818 ↗

NCT05228418 ↗

NCT02652585 ↗

NCT00234689 ↗

NCT02911597 ↗

NCT03970330 ↗

NCT00142844 ↗

NCT01625091 ↗

NCT01218984 ↗

NCT01822132 ↗

NCT01873729 ↗

NCT01908062 ↗

NCT00269607 ↗

NCT04409041 ↗

NCT03810495 ↗

NCT07092618 ↗

NCT03061734 ↗

NCT03008590 ↗

NCT01750060 ↗

NCT00218023 ↗

NCT01672723 ↗

NCT02461927 ↗

NCT06845124 ↗

NCT00456521 ↗

NCT00577408 ↗

NCT00684775 ↗

NCT00620750 ↗

NCT03275350 ↗

NCT05924893 ↗

NCT02026011 ↗

NCT00183222 ↗

NCT02107014 ↗

NCT00769158 ↗

NCT01218971 ↗

NCT00142948 ↗

NCT01246401 ↗

NCT01327326 ↗

NCT02792140 ↗

NCT01993108 ↗

NCT06620562 ↗

NCT00218153 ↗

NCT02317744 ↗

NCT00415597 ↗

NCT01377168 ↗

NCT05037032 ↗

NCT04450316 ↗

NCT01218958 ↗

NCT05955313 ↗

NCT02322047 ↗

NCT01999946 ↗

NCT00501696 ↗

NCT00667875 ↗

NCT02478489 ↗

NCT01563718 ↗

NCT02138396 ↗

NCT00120601 ↗

NCT06098079 ↗

NCT01950520 ↗

NCT00667771 ↗

NCT00000437 ↗

NCT01214083 ↗

NCT02885311 ↗

NCT00453609 ↗

NCT00006203 ↗

NCT01721330 ↗

NCT00006204 ↗

NCT06633900 ↗

NCT00006206 ↗

NCT00453804 ↗

NCT01895036 ↗

NCT04547985 ↗

NCT02638129 ↗

NCT00000438 ↗

NCT04739995 ↗

NCT00781898 ↗

NCT00854230 ↗

NCT05304364 ↗

NCT01024335 ↗

NCT05157698 ↗

NCT02401750 ↗

NCT01738867 ↗

NCT00521157 ↗

NCT00254670 ↗

NCT02362256 ↗

NCT00758966 ↗

NCT03185143 ↗

NCT04902625 ↗

NCT02818036 ↗

NCT00256451 ↗

NCT02437344 ↗

NCT07398404 ↗

NCT00000440 ↗

NCT00000442 ↗

NCT00270231 ↗

NCT03647774 ↗

NCT00714558 ↗

NCT00332228 ↗

NCT04791969 ↗

NCT01456507 ↗

NCT00474630 ↗

NCT00773422 ↗

NCT07641283 ↗

NCT00332605 ↗

NCT00568555 ↗

NCT00532779 ↗

NCT00000445 ↗

NCT01999114 ↗

NCT00624858 ↗

NCT00006449 ↗

NCT06216132 ↗

NCT00006489 ↗

NCT00332579 ↗

NCT04249882 ↗

NCT03278886 ↗

NCT05090280 ↗

NCT01843023 ↗

NCT01982643 ↗

NCT06245902 ↗

NCT00568958 ↗

NCT04313972 ↗

NCT00000447 ↗

NCT00715117 ↗

NCT04094584 ↗

NCT02330419 ↗

NCT04139213 ↗

NCT06605703 ↗

NCT04935931 ↗

NCT01077310 ↗

NCT04166071 ↗

NCT00523133 ↗

NCT00000448 ↗

NCT07433413 ↗

NCT02137252 ↗

NCT00369408 ↗

NCT00000449 ↗

NCT02206490 ↗

NCT06140420 ↗

NCT04139668 ↗

NCT02726035 ↗

NCT02454712 ↗

NCT04250792 ↗

NCT07269873 ↗

NCT00768508 ↗

NCT01723384 ↗

NCT01856712 ↗

NCT00000456 ↗

NCT01462227 ↗

NCT02268448 ↗

NCT00000455 ↗

NCT00000452 ↗

NCT00125515 ↗

NCT00000451 ↗

NCT00000450 ↗
Known as Depot naltrexone “addition of a monthly injection of depot naltrexone to treatment as usual (TAU) will significantly improve outcome” NCT00781898 ↗
Known as Extended release naltrexone “The opioid antagonist extended-release naltrexone (XR-NTX) in the treatment of opioid use disorder (OUD) is effective in terms of safety, abstinence from opioid use and...” PMID 35850782 ↗ Jul 2022
10

“We estimated the feasibility and effectiveness of extended-release naltrexone (XR-NTX) as relapse prevention among opioid-dependent male adults leaving a large urban jail.” PMID 25703440 ↗ Apr 2015

“Extended-release naltrexone (XR-NTX), an approved treatment for opioid or alcohol dependence, is a once-monthly injectable formulation of naltrexone.” PMID 24674234 ↗ Mar 2014

“Extended-release naltrexone (XR-NTX, Vivitrol; Alkermes Inc.) is an injectable monthly sustained-release mu opioid receptor antagonist.” PMID 25602580 ↗ Jan 2015

“XR-NTX (Extended-Release Naltrexone) doses of 380mg (Weeks 0, 3 and 6) via intramuscular (IM) injections in the gluteus.” NCT05262270 ↗

“One dose of intramuscular injection of 380mg extended-release naltrexone.” NCT01822132 ↗

“extended-release naltrexone (XR-NTX, Vivitrol®; Alkermes Inc.)” PMID 27282118 ↗ Jun 2016

“Extended Release Naltrexone for Opioid-Dependent Youth” NCT01843023 ↗

“Extended-Release Naltrexone (Vivitrol®)” NCT02032433 ↗

“Vivitrol (Extended Release Naltrexone)” NCT04094584 ↗

“XR-NTX (Extended-Release Naltrexone)” NCT01893827 ↗
Known as LDN “The goal of this pilot clinical trial is to find out how well low dose naltrexone works for people with pain due to spinal cord injury. The main questions it aims to answer...” NCT06723561 ↗
11

“Naltrexone, an orally semisynthetic opiate antagonist, is FDA-approved for the treatment of heroin/alcohol addiction, and low-dose naltrexone (LDN) has been observed to improve...” PMID 35001215 ↗ Jan 2022

“Low dose naltrexone(LDN) is an attractive emergent therapy with analgesic, anti-pruritic and anti-inflammatory properties for various dermatological disorders including psoriasis.” NCT04250792 ↗

“The investigators will compare the use of daily low dose naltrexone (LDN) (4.5 mg) compared with placebo in subjects that have symptomatic inflammatory bowel disease (IBD).” NCT01810185 ↗

“PURPOSE: Low-dose naltrexone (LDN) is commonly used to control pain and other symptoms, especially in patients with autoimmune diseases, but with limited evidence.” PMID 37045708 ↗ Apr 2023

“The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS).” NCT02502162 ↗

“This study will examine the effects of low-dose naltrexone (LDN) on children with autistic spectrum disorders.” NCT00318162 ↗

“Low-dose naltrexone (LDN) has demonstrated improvement of symptoms in conditions associated with IC/PBS.” NCT04313972 ↗

“Low Dose Naltrexone (LDN), naltrexone at a much lower dose” NCT05537935 ↗

“naltrexone hydrochloride, (Low-Dose Naltrexone, or LDN)” NCT01174914 ↗

“Low Dose Naltrexone (LDN)” NCT01650350 ↗

“Low-Dose Naltrexone (LDN)” NCT07221565 ↗
Known as Low dose Naltrexone (LDN) “Low dose Naltrexone (LDN)” NCT04604704 ↗
Known as low-dose naltrexone “Low dose naltrexone(LDN) is an attractive emergent therapy with analgesic, anti-pruritic and anti-inflammatory properties for various dermatological disorders including psoriasis.” NCT04250792 ↗
6

“The investigators will compare the use of daily low dose naltrexone (LDN) (4.5 mg) compared with placebo in subjects that have symptomatic inflammatory bowel disease (IBD).” NCT01810185 ↗

“Low-dose naltrexone (LDN) has demonstrated improvement of symptoms in conditions associated with IC/PBS.” NCT04313972 ↗

“Low Dose Naltrexone (LDN), naltrexone at a much lower dose” NCT05537935 ↗

“naltrexone hydrochloride, (Low-Dose Naltrexone, or LDN)” NCT01174914 ↗

“Low-dose Naltrexone” NCT02965768 ↗

NCT06366724 ↗
Known as Medisorb naltrexone “This was a Phase 3, multi-center extension of Alkermes' Study ALK21-003EXT (NCT01218971) to further assess the long-term safety of repeat monthly doses of Medisorb® naltrexone...” NCT00156923 ↗
3

“ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)” NCT01218971 ↗

“ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)” NCT01218997 ↗

“Medisorb® naltrexone (VIVITROL®)” NCT01218984 ↗
Known as naltrexone chlorhydrate “A pill of naltrexone chlorhydrate 50mg, associated to yellow liquid paraffin pills simulating borage seed and fish oil.” NCT01211769 ↗
Known as Naltrexone for extended-release injectable suspension “Naltrexone for extended-release injectable suspension” NCT01218984 ↗
Known as naltrexone HCl “Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week,...” NCT03581630 ↗
9

“ALO-02 capsules, intended to deter abuse, contain pellets of extended-release oxycodone hydrochloride (HCl), an opioid agonist, surrounding sequestered naltrexone HCl, an...” PMID 25724154 ↗ Apr 2015

“Participants will receive daily weight loss medication, Contrave, at a dose of 360 mg (Naltrexone HCl 32mg, Bupropion HCl 360mg).” NCT04553263 ↗

“Oxycodone hydrochloride (HCl) 20 mg IV and naltrexone HCl 2.4 mg IV administered simultaneously x 1 dose IV push over 4 min.” NCT01825447 ↗

“The drug being tested in this study is naltrexone HCl and bupropion HCl Extended- Release fixed dose combination (NB) .” NCT02745912 ↗

“oxycodone HCl and naltrexone HCl extended-release capsules” NCT01428583 ↗

“Naltrexone HCl 8 mg/bupropion HCl 90 mg tablets” NCT02616315 ↗

“Naltrexone HCL, 4.5 mg, Once a day.” NCT02502162 ↗

“Naltrexone HCl 50 MG Oral Tablet” NCT04547985 ↗

“Drug: Naltrexone-HCl” NCT00663117 ↗
Known as NALTREXONE HYDROCHLORIDE “Naltrexone hydrochloride was administered approximately 12 hours and 1 hour prior to and 12 hours after each dose of fentanyl to minimize the occurrence of unacceptable adverse...” NCT01780233 ↗
14

“Combination of (RS)-baclofen, naltrexone hydrochloride and D-sorbitol, termed PXT3003, improved myelination in the Pmp22 transgenic co-culture cellular model, and moderately...” PMID 25491744 ↗ Dec 2014

“Safety and tolerability of ALO-02 (oxycodone hydrochloride and sequestered naltrexone hydrochloride) extended-release capsules in older patients: a pooled analysis of two...” PMID 31456431 ↗ Sep 2019

“NB medication will combine BUPROPION HYDROCHLORIDE (360 mg/day) and NALTREXONE HYDROCHLORIDE (32 mg/day). Taken daily in pill form.” NCT03539900 ↗

“Evaluate the Efficacy and Safety of Naltrexone Hydrochloride Implant in Patients With Alcohol Use Disorder” NCT07433413 ↗

“The drug being tested in this study is called naltrexone hydrochloride/bupropion hydrochloride (NB).” NCT02616315 ↗

“one tablet of 50mg Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015)” NCT04276259 ↗

“Naltrexone hydrochloride is a generic, FDA-approved since 1998 drug, an opioid antagonist” NCT01174914 ↗

“Naltrexone Hydrochloride, 50 mg., intermittent with ecological momentary assessment (EMA)” NCT04791969 ↗

“NALTREXONE HYDROCHLORIDE 4,5 mg, coated oral tablets, 1xd. for 4 months” NCT05955313 ↗

“morphine sulfate and naltrexone hydrochloride (EMBEDA)” NCT01179191 ↗

“Drug: Naltrexone hydrochloride” NCT07398404 ↗

NCT00420992 ↗

NCT05007561 ↗

NCT00302133 ↗
Known as Naltrexone hydrochloride (HCl) “Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week,...” NCT03581630 ↗
Known as Naltrexone Hydrochloride ER “Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)” NCT06098079 ↗
Known as Naltrexone Low-Dose “Naltrexone Low-Dose (3mg) once daily at bedtime for 9 months” NCT01174914 ↗
Known as Naltrexone SR “Naltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)” NCT01764386 ↗
2

“Naltrexone SR 32 mg/ bupropion SR 360 mg/ day” NCT00456521 ↗

“Naltrexone SR 32 mg/bupropion SR 360 mg/ day” NCT00474630 ↗
Known as naltrexone sustained release (SR) “OBJECTIVE: This study assessed the effects of 32 mg naltrexone sustained release (SR)/360 mg bupropion SR (NB) on body weight in adults with obesity, with comprehensive...” PMID 28026920 ↗ Dec 2016
1

“combined naltrexone sustained-release (SR) (32 mg/day) plus bupropion SR (360 mg/day) (NB32) or placebo” PMID 23408728 ↗ May 2013
Known as naltrexone sustained-release “naltrexone sustained-release (SR, 32 mg/day), combined with bupropion SR (360 mg/day) plus BMOD” PMID 20559296 ↗ Jun 2010
Known as Naltrexone/ ReVia “Naltrexone/ ReVia” NCT00614328 ↗
Known as Nemexin “Naltrexone (Nemexin) oral tablet 50 mg daily for 2 days, Naltrexone (Nemexin) oral tablet 100 mg daily for 5 days” NCT03854942 ↗
Known as NTX “Additionally, CBD seems to be a particularly promising candidate for enhancing the effects of established medication, specifically Naltrexone (NTX), an opioid-antagonist, which...” NCT06845124 ↗
15

“This is a randomized, double blind placebo-controlled trial to examine the role of Relapse Prevention (RP) and Contingency Management (CMP) combined with Naltrexone (NTX) for...” NCT00218569 ↗

“This is a double-blind placebo-controlled study to evaluate the effect of Naltrexone (NTX) and counseling on highly active antiretroviral treatment (HAART) medication adherence” NCT01227044 ↗

“While currently approved medications, such as naltrexone (NTX), reduce craving and relapse risk to a certain extent, new approaches are needed to complement these pharmaca.” PMID 35410938 ↗ Apr 2022

“In the present study, 24 overweight women with a diagnosis of schizophrenia or schizoaffective disorder were randomized to placebo or naltrexone (NTX) 25 mg/d for 8 weeks.” PMID 25102328 ↗ Oct 2014

“A randomized, double-blind, parallel-group double-dummy study evaluated two medications, bupropion (BUP) and naltrexone (NTX), in treatment-seeking cigarette smokers” PMID 27213949 ↗ Jun 2016

“The opiate antagonist naltrexone (Ntx) has demonstrated efficacy in the treatment of alcohol dependence and as a component of treatment to reduce heavy drinking.” PMID 18796184 ↗ Sep 2008

“Consented adults (age 18-65) were randomized to (1) IV ketamine (KET) 0.5 mg/kg over 40 min, (2) IM naltrexone (NTX) 380 mg once, or (3) linkage alone (LA).” PMID 36419181 ↗ Nov 2022

“antagonist maintenance with naltrexone (NTX), which may be an optimal longer-term strategy for this population, requires prior opioid detoxification” NCT02543944 ↗

“the efficacy of the opioid antagonist naltrexone (NTX) as a tobacco dependence treatment remains unresolved.” NCT00270231 ↗

“Naltrexone (NTX) is a nonspecific pure opioid antagonist with a high affinity for the µ-opioid receptor.” NCT03810495 ↗

“Preclinical studies show that the opioid antagonist naltrexone (NTX) can block this cascade” PMID 25581657 ↗ Dec 2014

“Naltrexone (NTX) is a medication that helps people with opioid and alcohol dependence.” NCT06216132 ↗

“low-dose oral naltrexone (NTX), combined with a brief buprenorphine (BUP) taper” PMID 29674251 ↗ Apr 2018

“naltrexone (NTX) blocks the rewarding effects of MPH in mice.” NCT03769064 ↗

“Naltrexone (NTX)” NCT01738867 ↗
Known as O/NTX “efficacy of NMT may be improved by using extended-release naltrexone (XR/NTX) instead of oral naltrexone (O/NTX)” NCT01389167 ↗
1

“Oral Naltrexone (O-NTX)” NCT01893827 ↗
Known as Oral Naltrexone “Oral Naltrexone (O-NTX)” NCT01893827 ↗
Known as PO-NTX “Oral naltrexone (PO-NTX)” NCT02478489 ↗
Known as Revia “This study will compare cognitive behavioral therapy with a time-limited motivational enhancement therapy to which naltrexone (Revia) or placebo medication is added.” NCT00000456 ↗
17

“Although naltrexone (Revia) has been approved for the treatment of alcohol dependence, few pharmacotherapy studies have been undertaken with early problem drinkers.” NCT00000455 ↗

“It is available in the United States (US) as 2 formulations; a once daily oral formulation (Revia) and a once monthly intramuscular injection (Vivitrol).” NCT03810495 ↗

“This study will evaluate the effectiveness of the medication naltrexone (Revia) for treating alcoholism.” NCT00000438 ↗

“one tablet of 50mg Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015)” NCT04276259 ↗

“Naltrexone (Revia, Vivitrol) is recognized as having the potential for hepatotoxicity.” PMID 23036218 ↗ Nov 2012

“Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015)” NCT04322526 ↗

“naltrexone (Revia)” NCT00006204 ↗

“naltrexone (Revia)” NCT00006206 ↗

“naltrexone (Revia)” NCT00006449 ↗

“naltrexone (Revia)” NCT00000452 ↗

“naltrexone (Revia)” NCT00000449 ↗

“naltrexone (Revia)” NCT00000447 ↗

“naltrexone (Revia)” NCT00000445 ↗

“naltrexone (Revia)” NCT00000442 ↗

“naltrexone (Revia)” NCT00000440 ↗

“naltrexone (Revia)” NCT00004554 ↗

“naltrexone (ReVia)” NCT00027079 ↗
Known as sustained-release naltrexone “Sustained-release naltrexone is a treatment option that works by blocking the euphoric and overdose effects of opioids.” PMID 40342086 ↗ May 2025